Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
REGULATORY
Gene Therapy Collategene Gets 600,000 Yen Price Tag, Peak Sales Put at 1.2 Billion Yen
Collategene (beperminogene perplasmid), AnGes’ HGF gene therapy for chronic arterial occlusion, will join the NHI reimbursement price list on September 4 after skipping the previous listing round in May, carrying an NHI price tag of some 600,000 yen. The Central…
To read the full story
Related Article
- Payer Chides AnGes’s Course Change on Collategene, Urges Re-Think of System’s Set-Up
July 4, 2024
- AnGes Alters Strategy for Collategene, Halts Japan Sales for Fresh Submission
June 25, 2024
- AnGes Seeks Full Approval for Gene Therapy Collategene in Japan
June 1, 2023
- AnGes Calls off Japan Development of Collategene for Additional Indication
September 8, 2022
- Anges, Mitsubishi Tanabe to Launch Gene Therapy Collategene on Sept. 10
September 5, 2019
- After Listing Delayed, Collategene Expected to Reach Market by Year-End: AnGes Founder
July 22, 2019
- AnGes Delays Launch of Collategene, “Sale Preparations Will Take More Time”
May 15, 2019
- AnGes Bags Conditional Approval for Collategene Gene Therapy
March 27, 2019
- MHLW Panel OKs AnGes’ Gene Therapy Collategene for Conditional Approval
February 21, 2019
REGULATORY
- MHLW Asks for Ramp Up of HPV Vaccines after 5-Fold Rise in Demand
October 11, 2024
- MHLW Orders Label Revision for Systemic NSAIDs
October 11, 2024
- Xocova to Face CEA Price Cuts on Poor Cost Performance vs. SOC
October 10, 2024
- Kisunla to Follow Same Rules as Leqembi in Pricing and Post-Launch Review
October 10, 2024
- Supply of Anapeine Generic to Start by Year-End: Minister
October 9, 2024
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…